America Has a Peptide Obsession

A peptide is a short chain of amino acids. That definition covers insulin, first given to a patient in 1922, and it covers the peptide-branded face cream at the drugstore. It is a useful word for a marketer because it sounds precise and promises almost nothing.

The GLP-1 drugs gave the word a new kind of credibility. Semaglutide and tirzepatide are peptide-based medicines with large clinical trials behind them, and they changed how many Americans think about weight, appetite and the idea of willpower. They also taught a lot of people to be comfortable with a weekly injection.

The gray market next door

Next to those approved drugs sits a looser world of research-grade vials, wellness clinics and forum protocols. BPC-157 has been a favorite in that world for years, promoted for healing tendons and guts. Most of the evidence comes from animal studies. In 2023 the FDA listed it among bulk substances that may present significant safety risks in compounding. In July 2026 an FDA advisory panel voted 8 to 6 to recommend allowing it to be compounded for ulcerative colitis, even though FDA staff had proposed leaving it off the list. The vote is not binding, and any change would require formal rulemaking.

The appeal is easy to understand. Peptides feel targeted and biological, closer to a software patch than a pill. For people let down by ordinary medicine, a vial and a spreadsheet can feel like agency.

The science behind the successful peptides is extraordinary. It also took decades, large trials and regulators willing to say no. That part rarely makes it into the protocol.